Monitor for the filing of the preliminary prospectus supplement, which will disclose share count, price range, and expected gross proceeds. Given the lack of disclosed terms, the market impact will depend on final pricing and size — a large offering at a steep discount could pressure shares, while a modest raise at market could be well-received.
Price Chart
Executive Summary
Celldex Therapeutics announced a public offering of its common stock, with underwriters granted a 30-day option to purchase up to an additional 15% of shares. The offering is intended to fund commercial readiness for barzolvolimab, clinical development, platform expansion, and general corporate purposes. Exact size, pricing, and terms remain undisclosed and dependent on market conditions.
Key Facts
- Celldex Therapeutics (CLDX) has commenced an underwritten public offering of common stock.
- Underwriters have a 30-day option to purchase up to an additional 15% of shares.
- Proceeds will fund commercial launch readiness for barzolvolimab (if approved), clinical development, platform growth, and general corporate purposes.
- Leerink Partners and TD Cowen are joint bookrunning managers.
- Offering is made under an existing shelf registration (Form S-3, filed Nov 3, 2023).
- No specific number of shares, price, or total offering size has been disclosed.
Financial Impact
Undisclosed amount — dilution and total capital raise will depend on final pricing and share count.
Risk Factors
- Potential for significant dilution if offering is large and priced at a discount.
- Execution risk if market conditions deteriorate, delaying or scuttling the offering.
- No assurance the offering will close or be completed on favorable terms.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3266968 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▼ −19.96% | ▼ −20.71% | $31.65 (+1.46%) |
Jun 14, 2026 15w ago | Press Release | $32.12 $38.53 | ▲ +19.96% | ▲ +20.71% | $31.65 (−1.46%) |
Jun 11, 2026 16w ago | Institutional Cluster | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $31.65 (+5.64%) |
Jun 10, 2026 16w ago | Press Release | $29.96 $38.98 | ▲ +30.11% | ▲ +28.22% | $31.65 (+5.64%) |
May 7, 2026 21w ago | 8-K | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $31.65 (−6.83%) |
May 7, 2026 21w ago | Press Release | $33.97 $28.62 | ▼ −15.75% | ▼ −15.77% | $31.65 (−6.83%) |
Apr 6, 2026 25w ago | Press Release | $31.37 $32.77 | ▲ +4.46% | ▼ −4.52% | $31.65 (+0.89%) |
Apr 2, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.65 (+1.90%) |
Apr 1, 2026 26w ago | 424B5 | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.65 (+1.90%) |
Apr 1, 2026 26w ago | Press Release | $31.06 $32.88 | ▲ +5.86% | ▼ −4.02% | $31.65 (+1.90%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access